Shares of AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) traded down 0.7% on Friday . The stock traded as low as $24.51 and last traded at $25.19, with a volume of 851,747 shares changing hands. The stock had previously closed at $25.37.

AMAG has been the topic of a number of research reports. Zacks Investment Research raised AMAG Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 5th. Jefferies Group reissued a “buy” rating on shares of AMAG Pharmaceuticals in a research note on Wednesday, June 8th. Deutsche Bank AG dropped their price objective on AMAG Pharmaceuticals from $42.00 to $35.00 and set a “hold” rating on the stock in a research note on Monday, May 9th. JPMorgan Chase & Co. reissued a “hold” rating and issued a $37.00 price objective on shares of AMAG Pharmaceuticals in a research note on Thursday, May 5th. Finally, Leerink Swann dropped their price objective on AMAG Pharmaceuticals from $45.00 to $40.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 4th. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $38.20.

The firm’s 50-day moving average price is $22.56 and its 200 day moving average price is $23.72. The firm has a market cap of $871.02 million and a price-to-earnings ratio of 84.25.

AMAG Pharmaceuticals (NASDAQ:AMAG) last released its earnings results on Tuesday, May 3rd. The specialty pharmaceutical company reported $0.94 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.11 by $0.17. During the same period in the prior year, the company earned $1.17 earnings per share. The firm had revenue of $117.60 million for the quarter, compared to analysts’ expectations of $124.83 million. The firm’s revenue for the quarter was up 41.9% on a year-over-year basis. Analysts expect that AMAG Pharmaceuticals Inc. will post $5.20 EPS for the current fiscal year.

Other hedge funds and institutional investors recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP increased its position in AMAG Pharmaceuticals by 2.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 397,816 shares of the specialty pharmaceutical company’s stock worth $12,010,000 after buying an additional 8,435 shares in the last quarter. BNP Paribas Arbitrage SA increased its position in AMAG Pharmaceuticals by 6.6% in the fourth quarter. BNP Paribas Arbitrage SA now owns 62,716 shares of the specialty pharmaceutical company’s stock worth $1,893,000 after buying an additional 3,903 shares in the last quarter. Principal Financial Group Inc. increased its position in AMAG Pharmaceuticals by 69.2% in the fourth quarter. Principal Financial Group Inc. now owns 34,282 shares of the specialty pharmaceutical company’s stock worth $1,034,000 after buying an additional 14,017 shares in the last quarter. Bank of Montreal Can increased its position in AMAG Pharmaceuticals by 2,782.5% in the fourth quarter. Bank of Montreal Can now owns 75,781 shares of the specialty pharmaceutical company’s stock worth $2,287,000 after buying an additional 73,152 shares in the last quarter. Finally, Cornerstone Capital Management Holdings LLC. increased its position in AMAG Pharmaceuticals by 570.4% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 49,608 shares of the specialty pharmaceutical company’s stock worth $1,498,000 after buying an additional 42,208 shares in the last quarter.

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.